None listed
Conditions
Interventions
Trial treatments:
1 Venlafaxine (maximum dose 375 mg).
2. Imipramine (dose adjustment to adequate plasma levels of 200 – 300 ug/L).
3. Venlafaxine (maximum dose 375 mg) plus quetiapine (max. 600 mg
Sponsors
None listed
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age 18-65; 2. Major depressive disorder, single or recurrent episode, with psychotic features (Diagnostic and Statistical Manual of Mental Disorders, Fourth edition [DSM IV]); 3. Hamilton Rating Scale for Depression (HRSD) (17 item) 18; 4. Written informed consent.
Exclusion criteria
Exclusion criteria: 1. Bipolar I or II disorder; 2. Schizophrenia or other primary psychotic disorder; 3. Treatment of current episode with adequate trial of imipramine or venlafaxine. - imipramine at least 4 weeks with adequate bloodlevels; - venlafaxine at least 4 weeks ? 300 mg dd; 4. Drug/alcohol dependence last 3 months; 5. Mental retardation (IQ 3 mg lorazepam (or equivalent: see appendix ‘Moleman P. 1998. Praktische psychofarmacologie. Derde druk. Bohn Stafleu Van Loghum. page 19’); 10. Direct ECT indication (e.g. very severe suicidality or refusal of food and drinking resulting in a life threatening situation); 11. MAO-I < 1 week before start of medication free period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of responders. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1a. Change in HRSD scores; 1b. Change in CGI scores; 2. Time to response; 3. Adverse effects; 4. Group differences especially with regard to response to earlier treatments during current episode. | — |
Contacts
Public ContactJ. Wijkstra
University Medical Center Utrecht (UMCU), B01.206, Department of Psychiatry, P.O. Box 85500
Outcome results
None listed